<italic>IKZF1</italic> in acute lymphoblastic leukemia: the rise before the fall?

AbstractAcute lymphoblastic leukemia (ALL) is the most common malignancy in children and adolescents and in recent decades, the survival rates have risen to >90% in children largely due the introduction of risk adapted therapy. Therefore, knowledge of factors influencing risk of relapse is important. The transcription factor IKAROS is a regulator of lymphocyte development and alterations of its coding gene, <italic>IKZF1</italic>, are frequent in ALL and are associated with higher relapse risk. This concise review will discuss the normal function of IKAROS together with the effect of gene alterations in ALL such as relieved energy restriction and altered response to anti-leukemic drugs. Besides the biology, the clinical impact of gene alterations in the different subtypes of ALL will be discussed. Finally, possibilities for treating ALL with <italic>IKZF1</italic> alterations will be considered including novel therapies like cell signaling inhibitors and immunotherapy. [ABSTRACT FROM AUTHOR]